Background Proper assessment of the harms caused by the misuse of drugs can inform
policy makers in health, policing, and social care. We aimed to apply multicriteria decision …

For several decades, addiction has come to be viewed as a disorder of the dopamine
neurotransmitter system; however, this view has not led to new treatments. In this Opinion article, …

These British Association for Psychopharmacology guidelines cover the range and aims of
treatment for anxiety disorders. They are based explicitly on the available evidence and are …

Background Positron emission tomography (PET) allows the measurement of
benzodiazepine–γ-aminobutyric acid A (GABA A ) receptor kinetics. We employed flumazenil …

… Ballenger (chair), Jonathan RT Davidson, Yves Lecrubier, and David J. Nutt. Other faculty
invited by the chair were Julio Bobes, Deborah C. Beidel, Yukata Ono, and Herman GM …

Background Psilocybin may have antidepressant properties, but direct comparisons between
psilocybin and established treatments for depression are lacking. Methods In a phase 2, …

Background Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom
species. Recent studies have assessed the therapeutic potential of psilocybin for various …

Psychedelic drugs have a long history of use in healing ceremonies, but despite renewed
interest in their therapeutic potential, we continue to know very little about how they work in the …

Rationale Recent clinical trials are reporting marked improvements in mental health outcomes
with psychedelic drug-assisted psychotherapy. Objectives Here, we report on safety and …

Lysergic acid diethylamide (LSD) is the prototypical psychedelic drug, but its effects on the
human brain have never been studied before with modern neuroimaging. Here, three …